27
Feb
2020
Gilead, Moderna Rise to the Occasion, Esperion Goes Back-to-Back, & Sangamo’s Big Neurology Deal
This week’s Frontpoints is a compilation of two weeks of deals, financings, and personnel moves. Coronavirus Thoughts If we learn one big lesson from this public health crisis, it should be that we need to continue to invest in our public agencies dedicated to science and public health – CDC, NIH and FDA, for starters. We also need to continue... Read More
24
Feb
2020
Facing Up to a Political Crisis: BIO Chairman Jeremy Levin on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Feb
2020
Lilly, Genentech Alzheimer’s Drugs Fail, Revolution’s Big IPO, & an Obesity Drug Disappears
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Feb
2020
The Cell Therapy Puzzle: Jane Grogan on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Feb
2020
Sanofi’s Intriguing MS Drug, Merck’s Big Spinoff & Coronavirus Fog
Lots of shiny blinking objects are out there to pay attention to, but this was a week when a lot of fundamental hard work got done in biotech. Read about it in Frontpoints. Deal of the Week Merck is spinning off women’s health, biosimilars, and “trusted legacy brands” into a new company. The unnamed NewCo rolls together products expected to... Read More
6
Feb
2020
CAR-T for Autoimmunity: Bluestone Joins Sonoma Biotherapeutics, a $40M Bet
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Feb
2020
First Buy, Then Invest: Novartis, Gilead Join $35M Bet on Vineti’s Software
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jan
2020
Coronavirus Fear Spreads, CVS Feels the Heat & Black Diamond’s Sizzling IPO
Last week, I was dismissive of the coronavirus outbreak stories. The internet was teeming with what struck me as alarmism. I’m still not running for the hills. I’m still rolling my eyes at the speed and volume of misinformation about coronavirus on the web. But more facts have since emerged to make this a more urgent and serious situation. We... Read More
27
Jan
2020
Scientists at the Movies: Relay Therapeutics CEO Sanjiv Patel on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jan
2020
Much Ado About Coronavirus and 23andMe Hits the Wall
This was a quiet week in biopharma. Review it in your weekly Frontpoints. This Week in Alarmism Every year, we hear about an infectious disease scare that generates massive coverage, way out of proportion with the actual threat posed. Remember Mad Cow disease, SARS, Bird flu, Ebola, etc. etc? I’ve been in newsrooms providing saturation coverage of such things, and... Read More
16
Jan
2020
Lilly’s Half-Measure on Insulin, Illumina’s Up-Market Play, & the Little Deals from SF
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2020
A New Cholesterol-Lowering Drug at a Low Price: Tim Mayleben on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jan
2020
EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jan
2020
MRNA Vaccines Impress, Blueprint Wins First FDA OK, & Calif. Gov. Stares Down Biotech on the Eve of #JPM20
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Dec
2019
Designer Proteins as Better Therapies: David Baker on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Dec
2019
Sticking With Epigenetics During Lean Times: Jigar Raythatha on The Long Run
Today’s guest on The Long Run is Jigar Raythatha. Jigar is the CEO of Cambridge, Mass.-based Constellation Pharmaceuticals. This company is built to develop drugs against epigenetic targets. Simply put, this is a way to turn genes on or off without altering the underlying DNA. The pharmaceutical industry fancied this idea about a decade ago, as a way to shut... Read More
2
Dec
2019
IFM, Staying Small, Raises (Merely) $55.5M, Promotes Former Novartis Exec to CEO
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Nov
2019
Tamping Down Inflammation & Synaptic Dysfunction in Alzheimer’s: John Alam on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Nov
2019
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee... Read More